Plain-language summary

This Phase 1, Phase 2 trial is comparing tislezumab, golidocitinib, and other medications against other options for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

tislezumab (DRUG): Tislelizumab will be administered intravenously at a fixed dose of 200 mg every 3 weeks (Q3W). | golidocitinib (DRUG): Golidocitinib: Dose-escalating oral regimens: Dose level A: 150 mg every other day (QOD). Dose level B: 150 mg once daily (QD). | Selinexor (DRUG): Selinexor: Dose-escalating oral regimens: Dose A: 40 mg once weekly (QW) . Dose B: 60 mg QW for 2 consecutive weeks, followed by 1 week off.

Drugs / treatments

tislezumab, golidocitinib, Selinexor

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details